Conference abstractPublished 7 May 2022
Bryostatin improves moderate to severe alzheimerand#39;s disease patients
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Therapeutics to reduce the pathologic processes that underlie Alzheimer’s disease (AD) have not, to date, been approved by the FDA. While amyloid plaques and neurofibrillary tangles, together with clinical dementia, define AD, the loss of synaptic connections in the AD brain is the only pathologic deficit that closely correlates with cognitive deficits (Terry, et al., Ann. Neurol.,1991; Scheffe et al., Neurology, 2007; Holmes et al., Lancet, 2008). In extensive pre-clinical studies, the Synaptogenix platform drugs have been shown to reverse synaptic loss, prevent apoptosis, and to reduce amyloid plaques and tau tangles. Bryostatin activates the BDNF, NGF, IGF, HGF, and other Synaptic Growth Factor pathways to induce synaptogenesis, prevent apoptosis, and also activate enzymes to degrade amyloid and tau abnormalities. These pre-clinical findings could underlie the persistent benefits observed in several early AD trials: Phase I A, (2017), Compassionate Use Trials, (2017), and two pilot Phase II trials (2018, 2019). Bryostatin, in the absence of Namenda, caused significant (p<.01) improvement, 4.8 Severe Impairment Battery (SIB) points over baseline, with each of the Phase II trials using a single 11-week cycle of i.v. Bryostatin doses. Persistence of these benefits at least 30 days after the protocol is consistent with the demonstrated pre-clinical synaptogenic efficacy. The ongoing, NIH-supported 6 month trial includes two dosing cycles selected to extend the SIB improvement and minimize short-term placebo effects. Other planned trials will address new indications such as Fragile X / Autistic spectrum disorder (for which Synaptogenix has Orphan Drug Status) and Multiple Sclerosis – to demonstrate Bryostatin’s regenerative therapeutic potential. Pre-clinical evidence suggests that this regenerative potential may also apply to other causes of neurodegeneration such as multi-infarct dementia (See Sun and Alkon, TIPS, 2019).
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Neurology and Clinical Neuroscience
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Daniel L. Alkon”
